<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02750917</url>
  </required_header>
  <id_info>
    <org_study_id>ID ANALG-002-13</org_study_id>
    <nct_id>NCT02750917</nct_id>
  </id_info>
  <brief_title>Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty</brief_title>
  <official_title>A Comparative Study of Efficacy and Safety of Lornoxicam Versus Etoricoxib After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foisor Orthopedics Clinical Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foisor Orthopedics Clinical Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of lornoxicam compared with that
      of etoricoxib after total knee replacement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total primary knee arthroplasty (TKA) remains a model of severe pain for major orthopedic
      surgery. The concept of multimodal analgesia for the postoperative pain therapy is a routine
      in many hospitals but the question is still under debate about the ideal combination between
      techniques and drugs regarding early mobilization and low risk of complications.

      After obtaining Ethical Committee approval and informed consent, 110 patients American
      Society of Anesthesiologists score (ASA ) I-II undergoing knee replacement under spinal
      anesthesia were randomized to receive postoperative either lornoxicam (8 mg per os (PO) /12
      hours (h) for 48 h) or etoricoxib (120mg PO/24 h for 48 h) both administered in the
      postoperative care unit, at the end of surgery.

      The groups received postoperative analgesia when Numeric Rating Scale (NRS) over 3 with IV
      Perfalgan in fixed dose 1g every 8 h and morphine (loading dose 0,1mg/kg and titration until
      NRS under 3, followed by subcutaneous (SC) administration of ½ of the total loading dose on
      demand for the following 48 h).The lornoxicam group received gastric protection with IV
      pantoprazole.

      The effectiveness was evaluated by the time from the initiation of spinal anesthesia until
      the first analgesic dose at NRS over 3, the total amount of morphine in the first 24 and 48 h
      postoperative, the side effects and necessary amount of adjuvant medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine consumption</measure>
    <time_frame>At 48 hours postoperative</time_frame>
    <description>Amount of IV and subcutaneous (SC) morphine (mg) required to reach NRS under 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with side effects of drugs used</measure>
    <time_frame>At 48 hours postoperative</time_frame>
    <description>Number of patients with postoperative nausea and vomiting (PONV) or respiratory depression or gastric complaint or allergic reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>At 48 hours postoperative</time_frame>
    <description>Time from spinal anesthesia until the first rescue morphine analgesia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>GROUP LORNOXICAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP ETORICOXIB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lornoxicam</intervention_name>
    <description>At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.</description>
    <arm_group_label>GROUP LORNOXICAM</arm_group_label>
    <other_name>XEFO RAPID</other_name>
    <other_name>XEFO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoricoxib</intervention_name>
    <description>At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.</description>
    <arm_group_label>GROUP ETORICOXIB</arm_group_label>
    <other_name>Arcoxia</other_name>
    <other_name>Tauxib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-III

          -  weight (kilos) over 40 kg

          -  height (centimeters) over 155 cm

          -  non-anemic

          -  indication for primary TKA

        Exclusion Criteria:

          -  history of asthma

          -  peptic ulcer

          -  severe hepatic or renal dysfunction

          -  neuropathies

          -  bleeding disorders

          -  uncooperative

          -  drugs abuse

          -  sensibility to the drugs used

          -  long acting nonsteroidal antiinflammatory drugs (NSAID) in the last 4 days
             preoperative

          -  cerebrovascular and peripheric vascular disease

          -  arterial hypertension (HTA) not adequately controlled

          -  congestive heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ioan Cristian Stoica, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Foisor Orthopedics Clinical Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Ersan Ö, Akkaya T, Arık E, Ateş Y. Intra-articular levobupivacaine, lornoxicam and morphine analgesia after knee arthroscopy: a randomized, controlled trial. Acta Orthop Traumatol Turc. 2012;46(6):411-5.</citation>
    <PMID>23428763</PMID>
  </reference>
  <reference>
    <citation>Staunstrup H, Ovesen J, Larsen UT, Elbaek K, Larsen U, Krøner K. Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain. J Clin Pharmacol. 1999 Aug;39(8):834-41.</citation>
    <PMID>10434236</PMID>
  </reference>
  <reference>
    <citation>Sener M, Yilmazer C, Yilmaz I, Caliskan E, Donmez A, Arslan G. Patient-controlled analgesia with lornoxicam vs. dipyrone for acute postoperative pain relief after septorhinoplasty: a prospective, randomized, double-blind, placebo-controlled study. Eur J Anaesthesiol. 2008 Mar;25(3):177-82. Epub 2007 Oct 22.</citation>
    <PMID>17953792</PMID>
  </reference>
  <results_reference>
    <citation>Sivrikoz N, Koltka K, Güresti E, Büget M, Sentürk M, Özyalçın S. Perioperative dexketoprofen or lornoxicam administration for pain management after major orthopedic surgery: a randomized, controlled study. Agri. 2014;26(1):23-8. doi: 10.5505/agri.2014.09821.</citation>
    <PMID>24481580</PMID>
  </results_reference>
  <results_reference>
    <citation>Nørholt SE, Sindet-Pedersen S, Larsen U, Bang U, Ingerslev J, Nielsen O, Hansen HJ, Ersbøll AK. Pain control after dental surgery: a double-blind, randomised trial of lornoxicam versus morphine. Pain. 1996 Oct;67(2-3):335-43.</citation>
    <PMID>8951927</PMID>
  </results_reference>
  <results_reference>
    <citation>Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009 Oct;22(5):588-93. doi: 10.1097/ACO.0b013e328330373a. Review.</citation>
    <PMID>19606021</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>April 25, 2016</last_update_submitted>
  <last_update_submitted_qc>April 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Foisor Orthopedics Clinical Hospital</investigator_affiliation>
    <investigator_full_name>Munteanu Ana Maria, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>lornoxicam</keyword>
  <keyword>etoricoxib</keyword>
  <keyword>total knee arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoricoxib</mesh_term>
    <mesh_term>Lornoxicam</mesh_term>
    <mesh_term>Piroxicam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>August 24, 2016</submitted>
    <returned>October 17, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

